RTP Mobile Logo
Beyond the Guidelines: Investigator Perspectives on Clinical Issues in the Management of Colorectal, Gastric and Pancreatic Cancer
Released August 2016

Proceedings from a CME symposium held at the 2016 ASCO Annual Meeting. Featuring perspectives from Drs Dirk Arnold, Johanna C Bendell, George A Fisher, Richard M Goldberg, Axel Grothey and John L Marshall. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of colorectal, gastroesophageal and pancreatic cancer.

    Given the prevalent nature of the disease, extensive resources are allocated to colorectal cancer (CRC) research and education. Interestingly, however, although individually less frequently encountered, the collection of “non-CRC” gastrointestinal (GI) cancers account for more per annum deaths than those attributed to tumors of the colon and rectum combined. Among this collection of distinct diseases, two areas in particular — gastric and pancreatic cancer — have witnessed several recent advances that have altered or have the potential to drastically alter current treatment considerations and approaches.

    These video proceedings from a CME symposium held during the 2016 ASCO Annual Meeting feature discussions with leading researchers regarding the self-described practice patterns of a cohort of GI cancer clinical investigators and review of the published literature surrounding the clinical situations explored. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, hematology-oncology fellows and other healthcare providers with the formulation of up-to-date clinical management strategies for both CRC and select non-CRC GI cancers.


    • Compare and contrast the therapeutic decision-making of community-based oncologists and those of GI clinical investigators for patients with advanced colorectal, gastroesophageal and pancreatic cancer.
    • Develop a long-term care plan for individuals diagnosed with metastatic CRC (mCRC), considering the patient’s biomarker profile, exposure to prior systemic therapy, symptomatology, performance status and personal goals of treatment.
    • Use HER2 status, clinical factors and patient perspectives to optimize the selection and sequence of systemic therapy for locally advanced or metastatic gastric/gastroesophageal cancer.
    • Consider age, performance status and other clinical and logistical factors in the selection of systemic therapy for patients with locally advanced or metastatic pancreatic cancer.
    • Educate patients with pancreatic cancer about the potential side effects of various chemotherapeutic regimens, and provide preventive and emergent strategies to reduce or ameliorate these toxicities.
    • Appreciate the recent FDA approvals of TAS-102 for mCRC and MM-398 for metastatic pancreatic cancer, and develop strategies to incorporate these agents into current clinical algorithms.
    • Appraise the rationale for and clinical data with investigational anti-PD-1 and anti-PD-L1 antibodies for patients with GI cancers.
    • Recall new data with investigational agents demonstrating promising activity in colorectal, gastroesophageal and pancreatic cancer.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Professor Dirk Arnold
    CUF Hospitals Cancer Center
    Lisbon, Portugal

    Advisory Committee, Consulting Agreements and Honoraria: Bayer HealthCare Pharmaceuticals, EMD Serono Inc, Lilly, Roche Laboratories Inc.

    Johanna C Bendell, MD
    Director, GI Oncology Research
    Associate Director, Drug Development Unit
    Sarah Cannon Research Institute
    Nashville, Tennessee

    No relevant conflicts of interest to disclose.

    George A Fisher, MD, PhD
    Colleen G Haas Professor of Medicine
    Stanford University School of Medicine
    Stanford, California

    Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck; Data and Safety Monitoring Board: Celgene Corporation; Stock Ownership: Seattle Genetics.

    Richard M Goldberg, MD
    Professor of Medicine
    OSUCCC – James Cancer Hospital and Richard J Solove Research Institute
    Klotz Family Chair in Cancer Research
    The Ohio State University
    Columbus, Ohio

    Advisory Committee: Biothera Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Merck, Pfizer Inc, Sirtex Medical Ltd, Taiho Oncology Inc, Targovax; Consulting Agreements: Amgen Inc, Forty Seven Inc, Immunovative Therapies Ltd, Kanghong Pharma; Contracted Research: Bristol-Myers Squibb Company, Merck, Sanofi.

    Axel Grothey, MD
    Professor of Oncology
    Department of Medical Oncology
    Mayo Clinic
    Rochester, Minnesota

    Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Celgene Corporation, Genentech BioOncology, Lilly; Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Eisai Inc, Genentech BioOncology, Lilly, Merck, Sanofi.

    John L Marshall, MD
    Chief, Hematology and Oncology
    Director, Ruesch Center for the Cure of GI Cancers
    Lombardi Comprehensive Cancer Center
    Georgetown University
    Washington, DC

    Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, Genentech BioOncology; Consulting Agreements, Contracted Research and Speakers Bureau: Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. 

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Genentech BioOncology, Lilly, Merrimack Pharmaceuticals Inc and Taiho Oncology Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2016
    Expiration date: August 2017

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Click below to select videos to play: